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Viral Hepatitis in COVID-Era
L. Singh MD, J. Siu DO, A. Abbasi MD, R.Bajwa OMS3
Rene Peleman MD
Introduction
SARS-CoV-2, is a novel coronavirus responsible for causing the disease
COVID-19, which has been classified as a pandemic by the World Health
Organization. The virus, which originated from Wuhan, China, is the most
recently identified coronavirus. Two other recent coronaviruses, SARS-CoV
(severe acute respiratory syndrome) and MERS-CoV (middle eastern
respiratory syndrome) each resulted in epidemics. These three viruses share
more than 50% genome sequences. Disease severity of COVID-19 has varied
from mild to severe with patients experiencing respiratory and/or multisystem
organ dysfunction. Most commonly patients present with fever, cough, fatigue,
shortness of breath, muscle ache and headache with associated radiographic
findings of a bilateral multifocal pneumonia. Several studies have documented
the presence of elevated liver enzymes at time of presentation or during the
course of hospitalization for COVID-19. Additionally, there is 1 case report of a
patient presenting with acute hepatitis, who then later during admission tested
positive for SARS-CoV-2.We present the case of a 44 year old female with
acute hepatitis secondary to SARS-CoV-2 infection.

Case Description
The patient is a 44 year old female with a significant medical history of
Hashimoto’s thyroiditis, hypertension, GERD and neuropathy, who presented to
the hospital with the chief complaint of worsening shortness of breath. She
initially presented to an urgent care 5 days prior with symptoms of cough, body
aches, fever, chills, nausea and vomiting, and was found to test positive for
SARS-CoV-2. Vitals documented show pulse ox saturations of 92% at rest and
80% with ambulation on room air; other vital signs stable. Her initial chest x-ray
displayed patchy bilateral interstitial and alveolar airspace opacities. Significant
labs at time of admission included ALT/AST 588/321 IU/L (n<52/32
respectively), normal TBili and Alk Phos, Ferritin 712 ng/mL, CRP 6.3 mg/dL,
LDH 284 IU/L, WBC 3.4 K/uL, absolute lymphocytes 0.60, and D-dimer 1.27
ug/mL. The patient had no prior history of hepatitis, blood transfusions, recent
travel, diarrhea, alcohol abuse, IV drug use or family history of liver disease.
She also had no recent medication changes or use of over the counter
supplements. Her ALT/AST peaked at 1,404/360 on day 5 of hospitalization.
Work-up for the elevated transaminases included a viral hepatitis panel,
abdominal ultrasound with and without Doppler, ANA, autoimmune liver panel,
all of which resulted as negative. Given her rising transaminases, and that a
small percentage of cases of autoimmune hepatitis will be seronegative, a liver
biopsy was obtained for definitive diagnosis. During hospitalization, she was
placed on high dose steroids for her acute respiratory failure, thus covering for
possible etiology of autoimmune hepatitis. She remained hemodynamically
stable during hospitalization with weaning oxygen requirements. On day 6 a
preliminary pathology report was negative for autoimmune hepatitis, steroids
were discontinued at that time and she was discharged in medically stable
condition. Final pathology report is notable for, “morphologic findings
demonstrating mild lobular inflammation,” with a negative CMV
immunostaining. Most recent ALT/AST were 302/49, obtained 1 week after
discharge.

Pathology Photos

Lab values
INR

ALT AST
(IU/L)

(IU/L)

Alkaline
Total
phosphate Bilirubin

Direct
Bilirubin

(IU/L)

(mg/dL)

(mg/dL)

Admission 0.89

588

321

48

0.9

0.2

Day 1
Day 2
Day 3
Day 4
Day 5
Discharge
Post D/C

623
790
999
1206
1404
1313
302

323
332
374
354
360
277
49

46
46
45
46
43
43
-

0.9
0.6
0.6
0.7
0.6
0.6
-

0.2
0.3
0.3
-

0.93
0.92
0.93
0.92
0.93
0.92
-

Table 1: On admission pt had elevated ALT/AST, initially ruled out acute hepatitis, portal/hepatic vein
thrombosis, ANA negative. Pt was already getting steroids for COVID-19. LFTs peaked on day 5 of
admission and trended downwards and pt was discharged home. As we can see above 7 days after
discharge her LFTs trended downwards.

Interestingly this patient presented to the hospital with elevated ALT/AST
without any recent medication changes or taking over the counter
supplements. She was tested for SARS-CoV-2 on 4/9/20 with results coming
back on 4/14 the day of hospitalization. Liver biopsy was obtained on day 3 of
hospitalization as liver enzymes were climbing without a clear explanation.
While in the hospital she was placed on Azithromycin (4/15-4/16) and
plaquanil (4/14-4/17) these medications were discontinued given the rising
LFTs without a particular source. Lab work was obtained at 10am and
azithromycin and plaquanil were not administered until late in the evening,
therefore DILI was less likely on the differential.
Home medications included the following: ASA 81mg, Symbicort inhaler, Vit
D2, Zyrtec, Cardizem, Flonase, Levothyroxine, Amitriptyline and Lyrica.

Additional Workup/Labs & Liver biopsy
ANA, ALKM, ASMA and AMA negative
Hep A/B/C Negative
CMV Immunostain Negative
US Doppler liver: IVC, hepatic, portal and splenic veins patent.

Liver Biopsy: The portal tracts are unremarkable and do not demonstrates
significant inflammation. Bile ducts are identified and are normal. The lobular
parenchyma demonstrates mild lobular inflammation with occasional
hepatocyte drop-out and mild sinusoidal congestion; without steatosis,
granuloma or necrosis. Central veins are unremarkable, trichrome stain
reveals mild focal portal fibrosis. No stainable iron is seen.
In summary, morphologic findings demonstrate mild lobular inflammation.
These findings may be due to the patient's SARS-CoV-2 infection.

A special thanks to Dr. Kucy and Dr. Zakhia

Figure 1. Liver biopsy demonstrating normal portal tracts (yellow arrows) and mild
lobular inflammation of the without steatosis, granuloma or necrosis.

Discussion & Conclusion
The goal of management in cases of COVID-19 has primarily been focused
on respiratory support and specifically finding treatment options to help
reduce the “cytokine storm” that leads to the catastrophic cardiopulmonary
failure. As we look beyond into the extra-pulmonary manifestations of this
illness we see the magnitude of the fallout. Laboratory monitoring of
inflammatory markers such as ferritin, CRP, and LDH are assisting clinicians
in assessing the severity of disease and to gauge efficacy of treatment. It is
imperative to note that in these elevated inflammatory states, laboratory
monitoring of other organ systems is not over looked. A study recently
submitted to the Journal of Hepatology evaluated the clinical characteristics
of COVID-19 in 417 patients. Of these patients, 318 exhibited elevations in
liver functions test, 90 of whom had liver injury during the hospitalization. It
was noted that utilization of certain antiviral medications contributed
significantly to the detrimental effects.
As is the circumstances in our presented case, the patient was being treated
with a combination of azithromycin, Plaquenil, and a short course of
corticosteroids. LFT elevations were noted to progressively increase
throughout the hospital stay, despite a full workup including hepatitis panels,
autoimmune serology, etc. Ultimately leading to a liver biopsy to find
inflammation induced injury. Throughout the case close monitoring of LFTs
was essential in making treatment decisions such as pre-emptively
discontinuing azithromycin given its effects against the liver.
In the short span of a few months, several cases of COVID-19 induced liver
injuries have been seen across the world. This is has shed light on identifying
at risk populations. As we navigate through the “new normal” of COVID-19
world populations with pre-existing conditions, most notably anyone with
underlying liver disease should be closely monitored for hepatocellular failure.
Further research is needed in determining the causes of liver injury in COVID
19 patients.
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